Skip to main content
Close Search
Menu
About Us
Our Studies
Active Studies
Future Studies
Scientific Information
News
Participate
English
Español
Português (Brasil)
Home
/
News
Home
/
News
News
News
Argentina leads the fight against Respiratory Syncytial Virus with a vaccine for pregnant women
Argentina leads the fight against Respiratory Syncytial Virus with a vaccine for pregnant women
Argentina leads the fight against Respiratory Syncytial Virus with a vaccine for pregnant women
TN
Bronchiolitis vaccine: results show it is effective, but there is a warning sign
Bronchiolitis vaccine: results show it is effective, but there is a warning sign
Bronchiolitis vaccine: results show it is effective, but there is a warning sign
Clarin
First results: effectiveness of a vaccine against the virus that causes the highest number of hospitalizations in infants tested
First results: effectiveness of a vaccine against the virus that causes the highest number of hospitalizations in infants tested
First results: effectiveness of a vaccine against the virus that causes the highest number of hospitalizations in infants tested
La Nacion Society
Innovative vaccine tested in Argentina authorized and opens the way to the "new triple".
Innovative vaccine tested in Argentina authorized and opens the way to the "new triple".
Innovative vaccine tested in Argentina authorized and opens the way to the "new triple".
Clarin
Argentina was part of the trials: U.S. approved another bronchiolitis vaccine for people over 60 years old.
Argentina was part of the trials: U.S. approved another bronchiolitis vaccine for people over 60 years old.
Argentina was part of the trials: U.S. approved another bronchiolitis vaccine for people over 60 years old.
La Nacion
The unprecedented change for the health of babies and the view of an expert: "It is a revolution".
The unprecedented change for the health of babies and the view of an expert: "It is a revolution".
The unprecedented change for the health of babies and the view of an expert: "It is a revolution".
Clarin
Respiratory Syncytial Virus | Family Physician | Dr. Jorge Tartaglione | Dr. Gonzalo Perez Marc
Respiratory Syncytial Virus | Family Physician | Dr. Jorge Tartaglione | Dr. Gonzalo Perez Marc
Respiratory Syncytial Virus | Family Physician | Dr. Jorge Tartaglione | Dr. Gonzalo Perez Marc
Channel 9
Pregnant women. Respiratory Syncytial Virus: compulsory vaccination of pregnant women continues throughout the country.
Pregnant women. Respiratory Syncytial Virus: compulsory vaccination of pregnant women continues throughout the country.
Pregnant women. Respiratory Syncytial Virus: compulsory vaccination of pregnant women continues throughout the country.
La Voz
Bronchiolitis: how the new nasal vaccine for children aged 6 to less than 22 months will change the RSV paradigm
Bronchiolitis: how the new nasal vaccine for children aged 6 to less than 22 months will change the RSV paradigm
Bronchiolitis: how the new nasal vaccine for children aged 6 to less than 22 months will change the RSV paradigm
Infobae
Bronchiolitis: children called for trial of the first pediatric vaccine against Respiratory Syncytial Virus
Bronchiolitis: children called for trial of the first pediatric vaccine against Respiratory Syncytial Virus
Bronchiolitis: children called for trial of the first pediatric vaccine against Respiratory Syncytial Virus
La Nacion
Bronchiolitis: New Vaccine Revolutionizes Pediatrics
Bronchiolitis: New Vaccine Revolutionizes Pediatrics
Bronchiolitis: New Vaccine Revolutionizes Pediatrics
Science Team
Bronchiolitis: the vaccine analyzed by ANMAT could be a revolution in pediatrics
Bronchiolitis: the vaccine analyzed by ANMAT could be a revolution in pediatrics
Bronchiolitis: the vaccine analyzed by ANMAT could be a revolution in pediatrics
Science Team
Bronchiolitis: Respiratory Syncytial Virus Vaccine for Pregnant Women Evaluated in Argentina
Bronchiolitis: Respiratory Syncytial Virus Vaccine for Pregnant Women Evaluated in Argentina
Bronchiolitis: Respiratory Syncytial Virus Vaccine for Pregnant Women Evaluated in Argentina
Science Team
First maternal vaccine to protect infants against bronchiolitis virus approved in the U.S.
First maternal vaccine to protect infants against bronchiolitis virus approved in the U.S.
First maternal vaccine to protect infants against bronchiolitis virus approved in the U.S.
Science Team
Volunteers wanted: mRNA flu vaccine trial advances in the country in people over 65 years old
Volunteers wanted: mRNA flu vaccine trial advances in the country in people over 65 years old
Volunteers wanted: mRNA flu vaccine trial advances in the country in people over 65 years old
Science Team
How is the new Phase III clinical trial of mRNA vaccine against influenza in Argentina?
How is the new Phase III clinical trial of mRNA vaccine against influenza in Argentina?
How is the new Phase III clinical trial of mRNA vaccine against influenza in Argentina?
Science Team
U.S. approved bronchiolitis vaccine tested in Argentina
U.S. approved bronchiolitis vaccine tested in Argentina
U.S. approved bronchiolitis vaccine tested in Argentina
Science Team
Vaccines after Covid: good news with 3 key viruses and revolution ahead
Vaccines after Covid: good news with 3 key viruses and revolution ahead
Vaccines after Covid: good news with 3 key viruses and revolution ahead
Science Team
United States authorized bronchiolitis vaccine tested in Argentina
United States authorized bronchiolitis vaccine tested in Argentina
United States authorized bronchiolitis vaccine tested in Argentina
Science Team
Vaccine against bronchiolitis virus and severe respiratory infections in humans approved
Vaccine against bronchiolitis virus and severe respiratory infections in humans approved
Vaccine against bronchiolitis virus and severe respiratory infections in humans approved
Science Team
Pediatric respiratory disease alert: what are the warning signs?
Pediatric respiratory disease alert: what are the warning signs?
Pediatric respiratory disease alert: what are the warning signs?
Science Team
Study results: Plasma from convalescents
Study results: Plasma from convalescents
Study results: Plasma from convalescents
Science Team
Revolution in pediatric medicine for the first maternal bronchiolitis vaccine
Revolution in pediatric medicine for the first maternal bronchiolitis vaccine
Revolution in pediatric medicine for the first maternal bronchiolitis vaccine
Science Team
First maternal vaccine against one of the leading causes of death in infants makes headway
First maternal vaccine against one of the leading causes of death in infants makes headway
First maternal vaccine against one of the leading causes of death in infants makes headway
Science Team
PLASMA PROJECT
PLASMA PROJECT
PLASMA PROJECT
Science Team
MITS COVID 19 Project
MITS COVID 19 Project
MITS COVID 19 Project
Science Team
Gonzalo Pérez Marc in The Science League: pediatric vaccination COVID
Gonzalo Pérez Marc in The Science League: pediatric vaccination COVID
Gonzalo Pérez Marc in The Science League: pediatric vaccination COVID
Science Team
Fernando Polack: "The COVID was a wild animal and now it is a household pet".
Fernando Polack: "The COVID was a wild animal and now it is a household pet".
Fernando Polack: "The COVID was a wild animal and now it is a household pet".
Science Team
The bronchiolitis vaccine showed high levels of efficacy.
The bronchiolitis vaccine showed high levels of efficacy.
The bronchiolitis vaccine showed high levels of efficacy.
Science Team
New vaccine against bronchiolitis: 85.7% efficacy
New vaccine against bronchiolitis: 85.7% efficacy
New vaccine against bronchiolitis: 85.7% efficacy
Science Team
Bronchiolitis vaccine showed high levels of efficacy
Bronchiolitis vaccine showed high levels of efficacy
Bronchiolitis vaccine showed high levels of efficacy
Science Team
Pfizer announced that its vaccine against respiratory syncytial virus is effective.
Pfizer announced that its vaccine against respiratory syncytial virus is effective.
Pfizer announced that its vaccine against respiratory syncytial virus is effective.
Science Team
Study with first mRNA vaccine against respiratory syncytial virus begins in the country
Study with first mRNA vaccine against respiratory syncytial virus begins in the country
Study with first mRNA vaccine against respiratory syncytial virus begins in the country
Science Team
Post COVID: how clinical trials of bronchiolitis and influenza vaccines are progressing
Post COVID: how clinical trials of bronchiolitis and influenza vaccines are progressing
Post COVID: how clinical trials of bronchiolitis and influenza vaccines are progressing
Science Team
Why two leading Argentine physicians believe the pandemic is nearing the end
Why two leading Argentine physicians believe the pandemic is nearing the end
Why two leading Argentine physicians believe the pandemic is nearing the end
Science Team
Finding: 20% of infant deaths at home in the suburbs caused by RSV
Finding: 20% of infant deaths at home in the suburbs caused by RSV
Finding: 20% of infant deaths at home in the suburbs caused by RSV
Science Team
How trials seeking a single vaccine against coronavirus, influenza and bronchiolitis will look like
How trials seeking a single vaccine against coronavirus, influenza and bronchiolitis will look like
How trials seeking a single vaccine against coronavirus, influenza and bronchiolitis will look like
Science Team
A look at the "heart" of the plant-based vaccine: what the trial at the Military Hospital looks like
A look at the "heart" of the plant-based vaccine: what the trial at the Military Hospital looks like
A look at the "heart" of the plant-based vaccine: what the trial at the Military Hospital looks like
Science Team
The intimacy of in-country trials of vaccine that could have very powerful antibodies
The intimacy of in-country trials of vaccine that could have very powerful antibodies
The intimacy of in-country trials of vaccine that could have very powerful antibodies
Science Team
Gonzalo Pérez Marc, leader of the local trial of the plant-based vaccine against COVID-19
Gonzalo Pérez Marc, leader of the local trial of the plant-based vaccine against COVID-19
Gonzalo Pérez Marc, leader of the local trial of the plant-based vaccine against COVID-19
Science Team
Polack stated that Pfizer's vaccine had 97% efficacy in clinical trials in Argentina.
Polack stated that Pfizer's vaccine had 97% efficacy in clinical trials in Argentina.
Polack stated that Pfizer's vaccine had 97% efficacy in clinical trials in Argentina.
Science Team
What does the scientific paper on Pfizer and BioNTech's vaccine, headed by the Arge
What does the scientific paper on Pfizer and BioNTech's vaccine, headed by the Arge
What does the scientific paper on Pfizer and BioNTech's vaccine, headed by the Arge
Science Team
Fernando Polack: "Plasma works with 60% efficacy for mild covid patients".
Fernando Polack: "Plasma works with 60% efficacy for mild covid patients".
Fernando Polack: "Plasma works with 60% efficacy for mild covid patients".
Science Team
"The use of plasma transforms COVID-19 into a bad cold," said Fernando Polack.
"The use of plasma transforms COVID-19 into a bad cold," said Fernando Polack.
"The use of plasma transforms COVID-19 into a bad cold," said Fernando Polack.
Science Team
Fernando Polack presented his study with plasma: "Transforms the coronavirus into a cold".
Fernando Polack presented his study with plasma: "Transforms the coronavirus into a cold".
Fernando Polack presented his study with plasma: "Transforms the coronavirus into a cold".
Science Team
Fernando Polack: "We aim to have answers on the effectiveness of the vaccine by the end of this year".
Fernando Polack: "We aim to have answers on the effectiveness of the vaccine by the end of this year".
Fernando Polack: "We aim to have answers on the effectiveness of the vaccine by the end of this year".
Science Team
Fernando Polack: "They chose us because they know how we work".
Fernando Polack: "They chose us because they know how we work".
Fernando Polack: "They chose us because they know how we work".
Science Team
Fernando Polack: "We still do not know if convalescent plasma is useful to treat coronavirus".
Fernando Polack: "We still do not know if convalescent plasma is useful to treat coronavirus".
Fernando Polack: "We still do not know if convalescent plasma is useful to treat coronavirus".
Science Team
Dr. Polack's "antibody factory".
Dr. Polack's "antibody factory".
Dr. Polack's "antibody factory".
Science Team
Vaccines, pandemics and... beyond?
Vaccines, pandemics and... beyond?
Vaccines, pandemics and... beyond?
Science Team
Close Menu
About Us
Our Studies
Active Studies
Future Studies
Scientific Information
News
Participate
English
Español
Português (Brasil)
